Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Annovis Bio Inc (ANVS)
:ANVS
Holding ANVS?
Track your performance easily
ANVS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.21 - $20.00
Previous CloseN/A
Volume368.97K
Average Volume (3M)447.30K
Market Cap
$64.43M
Enterprise Value$91.95M
Total Cash (Recent Filing)$347.47K
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.73
Next Earnings
Apr 08, 2025EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.85
Shares Outstanding13,797,242
10 Day Avg. Volume683,179
30 Day Avg. Volume447,297
Standard Deviation0.39
R-Squared0.05
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.20
P/FCF Ratio0.00
Enterprise Value/Market Cap1.43
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.74
Forecast
1Y Price Target
$27.00Price Target Upside460.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Annovis Bio News
PremiumCompany Announcements
Annovis Bio Advances Alzheimer’s and Parkinson’s Drug Trials
PremiumCompany Announcements
Annovis Bio Appoints William Fricker as Interim CFO
Bulls Say, Bears Say
Bulls Say
Investment PotentialAnalysts have initiated a Buy rating for Annovis Bio, Inc. with a price target of $25.00.
Market PotentialThe stock is viewed as significantly undervalued from a longer-term perspective, due to the high unmet need in Alzheimer's disease and the large potential market.
Regulatory ApprovalThe FDA granted clearance to Annovis Bio to proceed with pivotal Phase 3 studies of its lead candidate buntanetap.
Bears Say
Additional FundingThe company will need to secure additional funding to support the conduction of pivotal trials with its lead candidate, buntanetap.
Capital RaisingThe company does need to raise capital to conduct P3 trials, which may involve equity financing and non-dilutive sources through potential partnerships and grants.
Funding NeedsSuccessfully navigating through funding needs remains very important to execute on its plans.
---
Ownership Overview
24.77% Insiders
3.44% Mutual Funds
0.86% Other Institutional Investors
67.46% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ANVS FAQ
What was Annovis Bio Inc’s price range in the past 12 months?
Annovis Bio Inc lowest stock price was $4.21 and its highest was $20.00 in the past 12 months.
What is Annovis Bio Inc’s market cap?
Annovis Bio Inc’s market cap is $64.43M.
When is Annovis Bio Inc’s upcoming earnings report date?
Annovis Bio Inc’s upcoming earnings report date is Apr 08, 2025 which is in 80 days.
How were Annovis Bio Inc’s earnings last quarter?
Annovis Bio Inc released its earnings results on Nov 11, 2024. The company reported -$0.97 earnings per share for the quarter, missing the consensus estimate of -$0.683 by -$0.287.
Is Annovis Bio Inc overvalued?
According to Wall Street analysts Annovis Bio Inc’s price is currently Undervalued.
Does Annovis Bio Inc pay dividends?
Annovis Bio Inc does not currently pay dividends.
What is Annovis Bio Inc’s EPS estimate?
Annovis Bio Inc’s EPS estimate is -0.29.
How many shares outstanding does Annovis Bio Inc have?
Annovis Bio Inc has 13,797,242 shares outstanding.
What happened to Annovis Bio Inc’s price movement after its last earnings report?
Annovis Bio Inc reported an EPS of -$0.97 in its last earnings report, missing expectations of -$0.683. Following the earnings report the stock price went down -6.25%.
Which hedge fund is a major shareholder of Annovis Bio Inc?
Currently, no hedge funds are holding shares in ANVS
---
Annovis Bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$27.00 (460.17% Upside)
$27.00 (460.17% Upside)
Blogger Sentiment
Bullish
ANVS Sentiment 70%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 5.9%
Last 30 Days ▲ 5.9%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.72%
12-Months-Change
Fundamentals
Return on Equity
-596.70%
Trailing 12-Months
Asset Growth
40.48%
Trailing 12-Months
Company Description
Annovis Bio Inc
Annovis Bio Inc is a United States based clinical stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neuro degenerative diseases. The pipeline products of the company include ANVS-401, ANVS-405 and ANVS-301.
---
ANVS Stock 12 Month Forecast
Average Price Target
$27.00
▲(460.17% Upside)
Technical Analysis
Bioxcel Therapeutics
―
Alzamend Neuro
―
SELLAS Life Sciences Group
―
Axsome Therapeutics
―
Anavex Life Sciences
―
Cassava Sciences
―
Best Analysts Covering ANVS
1 Year
1 Year Success Rate
2/16 ratings generated profit
1 Year Average Return
-38.82%
reiterated a buy rating 2 months ago
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -38.82% per trade.
---